Normal somatic growth in children receiving low-dose prophylactic co-trimoxazole.

Area of Science:

• Pediatric Nephrology
• Infectious Diseases
• Pharmacology

Background:

• Co-trimoxazole is a common antibiotic for preventing urinary tract infections (UTIs).
• Concerns exist regarding potential growth interference with high-dose co-trimoxazole.
• Low-dose prophylactic use in children requires specific growth assessment.

Purpose of the Study:

• To evaluate the impact of long-term, low-dose co-trimoxazole prophylaxis on somatic growth in girls.
• To assess growth parameters in girls with and without vesico-ureteric reflux (VUR).

Main Methods:

• Longitudinal growth and growth velocities were analyzed in 114 girls aged 2-12 years.
• Participants received daily low-dose co-trimoxazole (10 mg sulfamethoxazole/2 mg trimethoprim per kg) for at least 6 months, up to 6 years.
• Growth was compared between treatment periods and across different durations of prophylaxis.

Main Results:

• No significant variations in attained height, weight, or overall growth velocity were observed.
• Growth velocity remained consistent when comparing periods on and off prophylactic therapy.
• Growth was normal in girls with VUR and did not differ between prophylaxis durations (2, 3, or 4 years).

Conclusions:

• Long-term, low-dose co-trimoxazole prophylaxis does not adversely affect somatic growth in girls with a history of UTIs, with or without VUR.
• This prophylactic regimen appears safe for growth in otherwise healthy children.
• The findings support the continued use of co-trimoxazole for UTI prophylaxis when indicated.